SUMMARY If the PFE SGEN M&A closes by end of Q1 '24 ... Most likely closing timeframe ^1 and ^6 Return = 7-8% in 3-4 months PFE agreed to pay $229/share 12/1/23 SGEN closed at $212.72/share ^FN Refer to milestones in SGEN/PFE or HZNP/AMGN acquisition timelines shown in footnotes section RISKS What are the chances that ... FTC blocks the deal?  Very low FDA is giving this deal a high level of scrutiny ^2 SGEN and PFE are in oncology SGEN is a leader in Antibody drug conjugates

SUMMARY

Summary:

Summary:

Summary

Summary

SUMMARY Biotech stocks were up ~14% last week The huge biotech stock week was driven mainly by biotech M&A activity It's unlikely that...

(Originally posted 7/25/2022, updated 7/27/22) Summary BPIQ monitors mergers and acquisitions (M&A's) of smid-cap biopharmas Acquisition...

$XBI $74.80 | +1.0% Table of Contents: Covid Updates Pipeline Updates Business Updates Covid Updates #NVAX +1.6% Novavax COVID-19 Data...

$XBI $74.80 | +1.0% Table of Contents: Covid Updates Pipeline Updates Business Updates Covid Updates #NVAX +1.6% Novavax COVID-19 Data...

$XBI $63.32 | -5.53% Table of Contents: Covid Updates Pipeline Updates Business Updates Covid Updates #NVAX -10.7% Novavax COVID-19...

$XBI $63.32 | -5.53% Table of Contents: Covid Updates Pipeline Updates Business Updates Covid Updates #NVAX -10.7% Novavax COVID-19...